Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Malignant Intracranial Neoplasm and descendants · 91% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | Phase 1 | terminated | May 30, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | — | withdrawn | Jun 22, 2026 | West China Hospital | Study withdrawn prior to enrollment due to administrative review | Enrollment / accrual |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | Phase 2 | terminated | Jun 2, 2017 | National Cancer Institute (NCI) | Support was withdrawn from study resulting in early termination of study. Investigator had to close… | Drug supply |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Phase 1 | terminated | Nov 25, 2022 | Chimeric Therapeutics | IND application withdrawn | Other (stated, no rule matched) |
| NCT04994977 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid… | Phase 1 | terminated | Aug 6, 2021 | Weill Medical College of Cornell University | Study terminated due to low accrual | Enrollment / accrual |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain… | Phase 1 | suspended | Jan 9, 2020 | Northwell Health | Per IRB closed and opened a new study. | Other (stated, no rule matched) |
| NCT04105374 | Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual… | Phase 2 / Phase 3 | withdrawn | Sep 26, 2019 | NRG Oncology | NCI approval withdrawn | Other (stated, no rule matched) |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young… | — | terminated | Jul 7, 2023 | Pediatric Brain Tumor Consortium | The NCI will not extend the PBTC grant beyond March 31, 2026. | Other (stated, no rule matched) |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0… | Early Phase 1 | terminated | Apr 1, 2021 | Milton S. Hershey Medical Center | The study was stopped due to slow accrual. | Enrollment / accrual |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | Phase 1 | terminated | Jan 5, 2024 | University of Alabama at Birmingham | Not enough eligible participants to enroll. | Enrollment / accrual |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and… | Phase 1 | withdrawn | Jun 20, 2024 | Jeffrey Treiber | Inability to find participants meeting eligibility critieria | Other (stated, no rule matched) |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | Early Phase 1 | terminated | May 3, 2021 | Milton S. Hershey Medical Center | Enrollment was stopped due to direction from the scientific review committee of the Penn State… | Enrollment / accrual |
| NCT06098248 | Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis(cCeLLExvivo) | N/A | terminated | Oct 24, 2023 | VPIX Medical | Delays in specimen recruitment have increased costs and strained resources, risking study validity.… | Enrollment / accrual |
| NCT05669326 | Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery(NODDI-TRACT) | N/A | withdrawn | Dec 30, 2022 | GCS Ramsay Santé pour l'Enseignement et la Recherche | No recrutment | Other (stated, no rule matched) |
| NCT06776406 | Head Stabilization in Whole Brain RT | N/A | withdrawn | Jan 15, 2025 | Abramson Cancer Center at Penn Medicine | Grant ended | Other (stated, no rule matched) |
| NCT04964960 | Pembro+Chemo in Brain Mets | Phase 2 | terminated | Jul 16, 2021 | John L. Villano, MD, PhD | Slow Accrual | Enrollment / accrual |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma… | Phase 1 / Phase 2 | terminated | Apr 5, 2019 | Pediatric Brain Tumor Consortium | The decision to permanently close PBTC-053 was made following communication from the NCI that the… | Other (stated, no rule matched) |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy…(BRAVO) | Phase 1 | terminated | Jan 11, 2018 | University of Florida | Not feasible to accrue due to competing studies | Enrollment / accrual |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed…(PersoMed-I) | Phase 2 | terminated | May 26, 2020 | European Organisation for Research and Treatment of Cancer - EORTC | Poor accrual | Enrollment / accrual |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | Phase 2 | suspended | Apr 19, 2016 | Burzynski Research Institute | Clinical Hold | Other (stated, no rule matched) |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | — | terminated | May 9, 2013 | Dartmouth-Hitchcock Medical Center | Study was administratively closed by IRB | Other (stated, no rule matched) |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | Phase 3 | terminated | May 11, 2017 | DelMar Pharmaceuticals, Inc. | Change in clinical development plan | Other (stated, no rule matched) |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including… | Phase 1 / Phase 2 | terminated | Nov 6, 2017 | Alaunos Therapeutics | Sponsor decision due to slow accrual | Enrollment / accrual |
| NCT05554159 | A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From… | N/A | terminated | Sep 26, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive… | Phase 1 | terminated | Mar 18, 2021 | Columbia University | FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022… | Sponsor / business decision |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in… | Phase 1 | terminated | Sep 8, 2011 | M.D. Anderson Cancer Center | \<75 % participant accrual | Enrollment / accrual |
| NCT03593330 | Neurosurgical Transitional Care Programme(TCP) | N/A | terminated | Jul 20, 2018 | Barts & The London NHS Trust | Early data showed an improvement in length of stay and patient satisfaction, but the nursing time… | Other (stated, no rule matched) |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System… | Phase 1 / Phase 2 | terminated | Oct 1, 2018 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab… | Phase 1 | withdrawn | Jul 14, 2022 | Jonsson Comprehensive Cancer Center | Never opened | Other (stated, no rule matched) |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase 1 | terminated | Jan 31, 2018 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT04047602 | Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A…(RADREMI) | N/A | terminated | Aug 7, 2019 | Indiana University | trial stopped due to low accrual | Enrollment / accrual |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT01246869 | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and… | Phase 1 | terminated | Nov 23, 2010 | University of Utah | PI retired, study closed | Other (stated, no rule matched) |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in… | Phase 2 | suspended | Nov 17, 2021 | SonALAsense, Inc. | The study is suspended due to lack of funding but not due to safety concerns. | Safety / toxicity |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Giselle Sholler | Lack of enrollment | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | Phase 1 | terminated | Oct 15, 2018 | Providence Health & Services | Prinicipal Investigator departure from institution | Investigator |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of… | N/A | terminated | Jan 18, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | Phase 1 | terminated | Apr 10, 2020 | Dana-Farber Cancer Institute | Withdrawal of support from BMS | Other (stated, no rule matched) |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | Phase 1 / Phase 2 | terminated | May 11, 2016 | Cambridge University Hospitals NHS Foundation Trust | Slow recruitment | Enrollment / accrual |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of… | Phase 1 / Phase 2 | terminated | Jun 19, 2017 | National Cancer Institute (NCI) | The phase II portion was never started as we could no longer get the drug from the manufacturer. | Drug supply |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Y-mAbs Therapeutics | Business priorities | Sponsor / business decision |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | Phase 2 | withdrawn | Jun 11, 2020 | University of Chicago | unable to enroll | Enrollment / accrual |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse… | Phase 1 | withdrawn | Oct 1, 2021 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT05590273 | Forgotten Voices: Addressing Unmet Needs in Brain Tumor Caregivers(AIM 2) | N/A | terminated | Oct 21, 2022 | Virginia Commonwealth University | Insufficient caregiver participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials